Logo image of GBIO

GENERATION BIO CO (GBIO) Stock Price, Quote, News and Overview

NASDAQ:GBIO - Nasdaq - US37148K1007 - Common Stock - Currency: USD

0.6102  0 (-0.78%)

After market: 0.6096 0 (-0.1%)

GBIO Quote, Performance and Key Statistics

GENERATION BIO CO

NASDAQ:GBIO (2/21/2025, 8:23:03 PM)

After market: 0.6096 0 (-0.1%)

0.6102

0 (-0.78%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.65
52 Week Low0.59
Market Cap40.76M
Shares66.79M
Float56.85M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12/amc
IPO06-12 2020-06-12


GBIO short term performance overview.The bars show the price performance of GBIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

GBIO long term performance overview.The bars show the price performance of GBIO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GBIO is 0.6102 USD. In the past month the price decreased by -36.66%. In the past year, price decreased by -71.08%.

GENERATION BIO CO / GBIO Daily stock chart

GBIO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About GBIO

Company Profile

GBIO logo image Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 174 full-time employees. The company went IPO on 2020-06-12. The firm is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The firm is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The firm is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.

Company Info

GENERATION BIO CO

301 Binney Street

Cambridge MASSACHUSETTS 02142 US

CEO: Geoff McDonough

Employees: 174

Company Website: https://generationbio.com/

Investor Relations: https://investors.generationbio.com/

Phone: 18575295908

GENERATION BIO CO / GBIO FAQ

What is the stock price of GENERATION BIO CO today?

The current stock price of GBIO is 0.6102 USD. The price decreased by -0.78% in the last trading session.


What is the ticker symbol for GENERATION BIO CO stock?

The exchange symbol of GENERATION BIO CO is GBIO and it is listed on the Nasdaq exchange.


On which exchange is GBIO stock listed?

GBIO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GENERATION BIO CO stock?

13 analysts have analysed GBIO and the average price target is 7.14 USD. This implies a price increase of 1070.11% is expected in the next year compared to the current price of 0.6102. Check the GENERATION BIO CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GENERATION BIO CO worth?

GENERATION BIO CO (GBIO) has a market capitalization of 40.76M USD. This makes GBIO a Nano Cap stock.


How many employees does GENERATION BIO CO have?

GENERATION BIO CO (GBIO) currently has 174 employees.


What are the support and resistance levels for GENERATION BIO CO (GBIO) stock?

GENERATION BIO CO (GBIO) has a resistance level at 0.7. Check the full technical report for a detailed analysis of GBIO support and resistance levels.


Is GENERATION BIO CO (GBIO) expected to grow?

The Revenue of GENERATION BIO CO (GBIO) is expected to grow by 370.54% in the next year. Check the estimates tab for more information on the GBIO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GENERATION BIO CO (GBIO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GENERATION BIO CO (GBIO) stock pay dividends?

GBIO does not pay a dividend.


When does GENERATION BIO CO (GBIO) report earnings?

GENERATION BIO CO (GBIO) will report earnings on 2025-05-12, after the market close.


What is the Price/Earnings (PE) ratio of GENERATION BIO CO (GBIO)?

GENERATION BIO CO (GBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.19).


What is the Short Interest ratio of GENERATION BIO CO (GBIO) stock?

The outstanding short interest for GENERATION BIO CO (GBIO) is 4.05% of its float. Check the ownership tab for more information on the GBIO short interest.


GBIO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GBIO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to GBIO. GBIO has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GBIO Financial Highlights

Over the last trailing twelve months GBIO reported a non-GAAP Earnings per Share(EPS) of -2.19. The EPS decreased by -10.61% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -58.47%
ROE -139.28%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%46.51%
Sales Q2Q%252%
EPS 1Y (TTM)-10.61%
Revenue 1Y (TTM)513.27%

GBIO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to GBIO. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 4.39% and a revenue growth 370.54% for GBIO


Ownership
Inst Owners81.62%
Ins Owners2.79%
Short Float %4.05%
Short Ratio4.26
Analysts
Analysts80
Price Target7.14 (1070.11%)
EPS Next Y4.39%
Revenue Next Year370.54%